(AMLX) Amylyx Pharmaceuticals - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0321085088
AMLX: Medicines, ALS, Treatment, Neurodegenerative, Diseases
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company focused on developing therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Its lead product, RELYVRIO (sodium phenylbutyrate and tauroursodiol), is approved in the U.S. for the treatment of ALS in adults and is marketed as ALBRIOZA in Canada. The company is also advancing AMX0114, an investigational therapy targeting neurodegenerative diseases beyond ALS. Founded in 2013, Amylyx is headquartered in Cambridge, Massachusetts, and emphasizes a mission-driven approach to addressing unmet medical needs in neurodegeneration.
As of the latest data, Amylyx Pharmaceuticals, Inc. is listed under the ticker symbol AMLX on the NASDAQ exchange. The stock is classified as a common stock within the Pharmaceuticals sub-industry. The companys current resistance level is 5.2, with a support level at 2.2, indicating key price levels to watch for potential buying or selling opportunities.
From a technical standpoint, AMLX has an average 20-day volume of 711,930 shares, with a last price of 3.28. The stocks short-term trend is signaled by its SMA 20 at 3.48 and SMA 50 at 3.63, while the SMA 200 at 3.20 reflects a longer-term perspective. The ATR of 0.26 highlights moderate volatility in recent trading sessions.
Fundamentally, Amylyx has a market capitalization of $301.63 million USD. The forward P/E ratio of 2.77 suggests expectations for future earnings growth, while the P/B ratio of 1.54 indicates the stock is trading at a modest premium to its book value. The P/S ratio of 1.54 reflects the companys revenue multiple. However, the absence of a reported return on equity (RoE) may raise questions about profitability in the near term.
Additional Sources for AMLX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AMLX Stock Overview
Market Cap in USD | 343m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2022-01-07 |
AMLX Stock Ratings
Growth 5y | -37.4% |
Fundamental | -19.5% |
Dividend | 0.0% |
Rel. Strength Industry | 13.4 |
Analysts | 3.83/5 |
Fair Price Momentum | 2.77 USD |
Fair Price DCF | - |
AMLX Dividends
No Dividends PaidAMLX Growth Ratios
Growth Correlation 3m | -58.9% |
Growth Correlation 12m | 72% |
Growth Correlation 5y | -68% |
CAGR 5y | -39.67% |
CAGR/Max DD 5y | -0.41 |
Sharpe Ratio 12m | -0.05 |
Alpha | -1.44 |
Beta | 1.78 |
Volatility | 106.30% |
Current Volume | 517.1k |
Average Volume 20d | 701.5k |
As of March 15, 2025, the stock is trading at USD 3.63 with a total of 517,117 shares traded.
Over the past week, the price has changed by -6.33%, over one month by -2.55%, over three months by -13.28% and over the past year by +14.35%.
Neither. Based on ValueRay Fundamental Analyses, Amylyx Pharmaceuticals is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -19.52 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AMLX as of March 2025 is 2.77. This means that AMLX is currently overvalued and has a potential downside of -23.69%.
Amylyx Pharmaceuticals has received a consensus analysts rating of 3.83. Therefor, it is recommend to buy AMLX.
- Strong Buy: 2
- Buy: 1
- Hold: 3
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, AMLX Amylyx Pharmaceuticals will be worth about 3.2 in March 2026. The stock is currently trading at 3.63. This means that the stock has a potential downside of -12.67%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 8 | 120.4% |
Analysts Target Price | 8 | 120.4% |
ValueRay Target Price | 3.2 | -12.7% |